| Literature DB >> 33814906 |
Yiben Huang1, Jianing Wang1,2, Jiamin Shen1,2, Jiedong Ma1,2, Xiaqi Miao1,2, Keke Ding1,2, Bingqian Jiang1,2, Binbin Hu1,2, Fangyi Fu1,2, Lingzhi Huang1, Meiying Cao3, Xiaodiao Zhang1.
Abstract
BACKGROUND: We aimed to investigate the association between red cell index (RCI) and the severity of Chronic Obstructive Pulmonary Disease (COPD), and compare predictive value of RCI, neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) for the severity of COPD.Entities:
Keywords: COPD; RCI; biomarker; pulmonary function
Mesh:
Year: 2021 PMID: 33814906 PMCID: PMC8010121 DOI: 10.2147/COPD.S292666
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Figure 1Flow chart showing the literature search and selection. Specific reasons for exclusion of studies are also shown.
Comparison of COPD Patients and Healthy Controls
| Total | Group A | Group B | p | |
|---|---|---|---|---|
| Age (years) | 70.14 ± 8.38 | 70.17 ± 8.41 | 70.12 ± 8.39 | 0.968 |
| Gender (male, | 178 (85.99) | 87 (87.00) | 91 (85.05) | 0.467 |
| RBC (1012/L) | 4.50 ± 0.57 | 4.28 ± 0.44 | 4.70 ± 0.60 | <0.001 |
| Hb (g/L) | 137.85 ± 19.0 | 130.19 ± 13.82 | 145.08 ± 20.39 | <0.001 |
| PLT (109/L) | 219.84 ± 65.05 | 232.75 ± 75.34 | 207.66 ± 51.01 | 0.006 |
| Lym (109/L) | 2.61 ± 9.30 | 1.62 ± 0.73 | 3.54± 12.91 | 0.138 |
| RCI | 1.86 ± 1.12 | 2.10 ± 1.44 | 1.64 ± 0.64 | 0.004 |
| NLR | 2.80 ± 2.95 | 4.02 ± 3.80 | 1.65 ± 0.74 | <0.001 |
| PLR | 134.29 ± 83.42 | 170.89 ± 101.61 | 99.74 ± 37.04 | <0.001 |
| RDW | 13.12 ± 1.27 | 13.27 ± 0.08 | 12.98 ± 0.15 | 0.055 |
Notes: Group A, patients with COPD; Group B, healthy people.
Abbreviations: COPD, chronic obstructive pulmonary disease; RBC, red blood cell; Hb, hemoglobin; PLT, platelet; Lym, lymphocyte; RCI, red cell index; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; RDW, red blood cell distribution width.
T-Tests for Groups Divided According to RCI with Severity of Disease and Other Functions
| RCI < 1.75 | RCI > 1.75 | ||
|---|---|---|---|
| Baseline characteristic | |||
| Age | 69.67 ± 9.46 | 71.28 ± 7.38 | 0.340 |
| Sex (male, n%) | 40 (74.07) | 42 (91.30) | 0.021 |
| Duration of Disease | 10.13 ± 8.69 | 15.69 ± 13.55 | 0.021 |
| Smoking | 36 (66.67) | 38 (82.61) | 0.054 |
| Hypertension | 22 (40.74) | 16 (34.78) | 0.545 |
| Diabetes mellitus | 9 (16.67) | 6 (13.04) | 0.617 |
| Lung Function | |||
| FEV1 (L) | 1.05 ± 0.49 | 0.84 ± 0.34 | 0.016 |
| FVC (L) | 1.97 ± 0.73 | 1.67 ± 0.54 | 0.027 |
| FEV1% (< 50%) | 44.25 ± 14.88 | 34.10 ± 12.57 | 0.001 |
| FEV1/FVC ratio (%) | 52.16 ± 9.63 | 49.46 ± 7.69 | 0.150 |
| PaO2 | 73.21 ± 12.33 | 72.57 ± 17.47 | 0.838 |
| PaCO2 | 42.44 ± 5.47 | 46.73 ± 11.39 | 0.025 |
| Severity of disease | |||
| GOLD | 2.76 ± 0.84 | 3.31 ± 0.64 | 0.001 |
| BODE | 3.56 ± 2.22 | 4.25 ± 2.45 | 0.165 |
| ADO | 4.41 ± 1.41 | 5.05 ± 1.38 | 0.033 |
| DOSE | 2.24 ± 1.64 | 3.21 ± 1.74 | 0.051 |
| mMRC | 1.58 ± 0.97 | 1.77 ± 0.96 | 0.343 |
| CAT | 17.45 ± 6.64 | 18.18 ± 6.91 | 0.601 |
| SGQR | 36.30 ± 19.82 | 39.42 ± 2.55 | 0.415 |
Abbreviations: RCI, red cell index; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FEV1%, forced expiratory volume in 1 second in percent of the predicted value; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial pressure of carbon dioxide in arterial blood; GOLD, Global Initiative for Chronic Obstructive Lung Disease; BODE, BMI, airflow obstruction, dyspnea and exercise capacity; ADO, age, dyspnoea and obstruction; DOSE, dyspnoea, obstruction, smoking and exacerbations; mMRC, modified Medical Research Council dyspnoea scale; CAT, COPD assessment test; SGRQ, St. George’s Respiratory Questionnaire.
Figure 2Correlations of the RCI, NLR and PLR with FEV1%.
Figure 3ROC curves of the RCI, NLR, PLR, Lym and RDW of COPD patients, for predicting severe or mild COPD. The area under ROC curve of RCI: 0.729; 95% CI: 0.619–0.839; p = 0.001.
Univariate Logistic Regression Analysis Assesses Different Prognostic Predictors of COPD
| OR | 95% CI | |||
|---|---|---|---|---|
| Age | 0.987 | 0.936–1.041 | 0.641 | |
| Sex | 0.672 | 0.222–2.036 | 0.482 | |
| Duration of Disease | 1.071 | 1.006–1.139 | 0.031 | |
| Smoking | 1.067 | 0.369–3.081 | 0.905 | |
| Hypertension | 0.937 | 0.383–2.291 | 0.887 | |
| BMI | 0.861 | 0.760–0.977 | 0.020 | |
| CAT | 1.034 | 0.969–1.104 | 0.315 | |
| SGRQ | 1.027 | 1.001–1.055 | 0.043 | |
| CCQ | 1.096 | 0.997–1.204 | 0.059 | |
| ADO | 1.652 | 1.171–2.333 | 0.004 | |
| DOSE | 2.945 | 1.418–6.113 | 0.004 | |
| FEV1/FVC | 0.801 | 0.731–0.878 | <0.001 | |
| PaO2 | 0.970 | 0.941–1.000 | 0.051 | |
| PaCO2 | 1.380 | 1.175–1.620 | <0.001 | |
| RBC | 1.811 | 0.627–5.231 | 0.273 | |
| Hb | 1.019 | 0.985–1.054 | 0.284 | |
| PLT | 0.994 | 0.988–1.000 | 0.066 | |
| Lym | 0.265 | 0.116–0.602 | 0.002 | |
| RCI | 2.533 | 1.378–4.656 | 0.003 | |
| NLR | 1.380 | 1.038–1.836 | 0.027 | |
| PLR | 1.006 | 0.999–1.013 | 0.082 | |
| RDW | 1.038 | 0.605–1.781 | 0.893 |
Notes: Divided COPD patients into two groups according to GOLD stage: Group A, GOLD I + GOLD II; Group B, GOLD III + GOLD IV. Using univariate logistic regression analysis to assess the effect of prognostic indicators on the severity of COPD.
Abbreviations: BMI, body mass index; CAT, COPD assessment test; SGRQ, St. George’s Respiratory Questionnaire; CCQ, Clinical COPD Questionary; ADO, age, dyspnea and airflow obstruction; DOSE, MRC Dyspnea Scale, airflow obstruction, smoking status and exacerbations; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial pressure of carbon dioxide in arterial blood; RBC, red blood count; Hb, hemoglobin; PLT, platelet; Lym, lymphocyte; RCI, red cell index; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; RDW, red blood cell distribution width.
Adjusted Odds Ratio (95% Confidence Interval) for Severe COPD (GOLD III + IV)
| OR (95% CI) | ||
|---|---|---|
| Model1 | 2.533 (1.378–4.656) | 0.003 |
| Model2 | 2.348 (1.239–4.450) | 0.009 |
| Model3 | 4.272 (1.570–11.627) | 0.004 |
Notes: Model 1 is univariate analysis. Model 2 is adjusted by age, sex, duration of disease and body mass index. Model 3 is adjusted by age, sex, duration of disease, BMI, FEV1/FVC and PaCO2.